Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | LGMN | Q99538 | 2/20 | 0.53 |
| ▸ | CDC7 | O00311 | 2/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | S100B | P04271 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538450 | 0.93 | NPC1 (0.63) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL3534452 | 0.84 | ALDH1A1 (0.56) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL3536839 | 0.84 | MAPT (0.56) | NPC1LGMNCDC7CDK9HTT | |
| Hydrochloric Acid SCHEMBL3539657 | 0.83 | ALDH1A1 (0.55) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL3536670 | 0.83 | NPC1 (0.52) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL3542734 | 0.82 | NPC1 (0.51) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL14982136 | 0.80 | ALDH1A1 (0.56) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL17774975 | 0.78 | LGMN (0.61) | LGMNHTTALDH1A1MAPTL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL3545922 | 0.77 | ALDH1A1 (0.49) | NPC1CDC7CDK9HTTALDH1A1 | |
| SCHEMBL3533602 | 0.77 | LGMN (0.87) | NPC1LGMNHTTALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | claimed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | claimed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | claimed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | NPC1 4575/4885LGMN 3741/4885CDC7 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.